CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway

Brain, Behavior, and Immunity

Volumn 50, Issue , 2015, Pages 125-140

  Cathomas, Flurin ^a   Fuertig, Rene ^b   Sigrist, Hannes ^a   Newman, Gregory N ^a   Hoop, Vanessa ^a,c   Bizzozzero, Manuela ^a   Mueller, Andreas ^c,d   Luippold, Andreas ^b   Ceci, Angelo ^b   Hengerer, Bastian ^b   Seifritz, Erich ^a,c   Fontana, Adriano ^c,d   Pryce, Christopher R ^a,c  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CD40; Depression; Fatigue; Fear learning; IDO; Kynurenine pathway; Reward motivation; Sickness behavior syndrome; TNF

Indexed keywords

CD40 ANTIGEN; ETANERCEPT; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; SACCHARIN; SEROTONIN; TUMOR NECROSIS FACTOR; CD40 LIGAND; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATIGUE; FEAR CONDITIONING TEST; FLUID INTAKE; HYPERSOMNIA; LOCOMOTION; MAJOR DEPRESSION; MALE; MOTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REWARD; SICKNESS BEHAVIOR SYNDROME; SYNDROME; WEIGHT REDUCTION; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CONDITIONING; DRINKING BEHAVIOR; DRUG EFFECTS; FEAR; ILLNESS BEHAVIOR; IMMUNOLOGY; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BEHAVIOR, ANIMAL; CD40 LIGAND; CONDITIONING (PSYCHOLOGY); DEPRESSIVE DISORDER, MAJOR; DRINKING BEHAVIOR; FEAR; ILLNESS BEHAVIOR; KYNURENINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; SIGNAL TRANSDUCTION; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937231104     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.06.184     Document Type: Article

References (84)

1. Agudelo L.Z., Femenia T., Orhan F., Porsmyr-Palmertz M., Goiny M., Martinez-Redondo V., Correla J.C., Izadi M., Bhat M., Schuppe-Koistinen I., Pettersson A.T., Ferreira D.M.S., Krook A., Barres R., Zierath J.R., Erhardt S., Lindskog M., Ruas J.L. Skeletal muscle PGC-1A1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 2014, 159:33-45.
2. Aubert A., Dantzer R. The taste of sickness: lipopolysaccharide-induced finickiness in rats. Physiol. Behav. 2005, 84:437-444.
3. Azzinnari D., Sigrist H., Staehli S., Palme R., Hildebrandt T., Leparc G., Hengerer B., Seifritz E., Pryce C.R. Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function. Neuropharmacology 2014, 85:328-341.
4. Berk M., Williams L.J., Jacka F.N., O'Neill A., Pasco J.A., Moylan S., Allen N.B., Stuart A.L., Hayley A.C., Byrne M.L., Maes M. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med. 2013, 11:200.
5. Biagioli M., Pinto M., Cesselli D., Zaninello M., Lazarevic D., Roncaglia P., Simone R., Viacouli C., Plessy C., Bertin N., Beltrami A., Kobayashi K., Gallo V., Santoro C., Ferrer I., Rivella S., Beltrami C.A., Carninci P., Raviola E., Gustincich S. Unexpected expression of a- and b-globin in mesencephalic dopaminergic neurons and glial cells. Proc. Natl. Acad. Sci. USA 2009, 106:15454-15459.
6. Biesmans S., Meert T.F., Bouwknecht J.A., Acton P.D., Davoodi N., De Haes P., Kuijlaars J., Langlois X., Matthews L.J.R., Ver Donck L., Hellings N., Nuydens R. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm. 2013, 271359:1-14.
7. Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron 2009, 64:93-109.
8. Bruce T.O. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr. Psychiatry Rep. 2008, 10:258-264.
9. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130:226-238.
10. Carmichael M.D., Davis J.M., Murphy E.A., Brown A.S., Carson J.A., Mayer E.P., Ghaffar A. Role of brain IL-1B on fatigue after exercise-induced muscle damage. Am. J. Physiol. Integr. Comp. Physiol. 2006, 291:R1344-R1348.
11. Cathomas F., Stegen M., Sigrist H., Schmid L., Seifritz E., Gassmann M., Bettler B., Pryce C.R. Altered emotionality and neuronal excitability in mice lacking KCTD12, an auxiliary subunit of GABAB receptors associated with mood disorders. Transl. Psychiatry 2015, 5:e510. 10.1038/tp.2015.8.
12. Cavadini G., Petrzilka S., Kohler P., Jud C., Tobler I., Birchler T., Fontana A. TNF-a suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc. Natl. Acad. Sci. USA 2007, 104:12843-12848.
13. Chatzigeorgiou A., Lyberi M., Chatzilymperis G., Nezos A., Kamper E. CD40/CD40L in signaling and its implication in health and disease. BioFactors 2009, 35:474-483.
14. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
15. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007, 21:153-160.
16. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-57.
17. Dantzer R., Heijnen C.J., Kavelaars A., Laye S., Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. 2014, 37:39-46.
18. Demyttenaere K., De Fruyt J., Stahl S.M. The many faces of fatigue in major depressive disorder. Int. J. Neuropsychopharmacol. 2005, 8:93-105.
19. Dobos N., de Vries E.F.J., Kema I.P., Patas K., Prins M., Nijholt I.M., Dierckx R.A., Korf J., den Boer J.A., Luiten P.G.M., Eisel U.L.M. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J. Alzheimer's Dis. 2012, 28:905-915.
20. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
21. DSM-5 Diagnostic and Statistical Manual of Mental Disorders, fifth ed. Revision American Psychiatric Association, Washington, DC 2013, American Psychiatric Association, Washington, DC.
22. Ehrlich I., Humeau Y., Grenier F., Ciocchi S., Herry C., Lüthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron 2009, 62:757-771.
23. Endo T., Maekawa F., Voikar V., Haijama A., Uemura Y., Zhang Y., Miyazaki W., Suyama S., Shimazaki K., Wolfer D.P., Yada T., Tohyama C., Lipp H.-P., Kakeyama M. Automated test of behavioral flexibility in mice using a behavioral sequencing task in IntelliCage. Behav. Brain Res. 2011, 221:172-181.
24. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012, 33:315-327.
25. Franklin K.B.J., Paxinos G. The Mouse Brain: in Stereotaxic Coordinates 2008, Elsevier, Amsterdam.
26. Fuertig, R., Azzinnari, D., Sigrist, H., Seifritz, E., Luippold, A., Hengerer, B., Ceci, A., Pryce, C.R., in preparation. Mouse chronic social stress increases blood-brain kynurenine pathway activity and conditioned fear, and both effects are reversed by inhibition of indoleamine 2 3-dioxygenase.
27. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 1991, 56:2007-2017.
28. Gal E.M., Sherman A.D. Synthesis and metabolism of L-kynurenine in rat brain. J. Neurochem. 1978, 30:607-613.
29. Gast H., Müller A., Lopez M., Meier D., Huber R., Dechent F., Prinz M., Emmenegger Y., Franken P., Birchler T., Fontana A. CD40 activation induces NREM sleep and modulates genes associated with sleep homeostasis. Brain Behav. Immun. 2013, 27:133-144.
30. Gold S.M., Irwin M.R. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol. Allergy Clin. North America 2009, 29:309-320.
31. Grewal L.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16:111-135.
32. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
33. Hou D.-Y., Muller A.J., Sharma M.D., DuHadaway J., Banerjee T., Johnson M., Mellor A.L., Prendergast G.C., Munn D.H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007, 67:792-801.
34. ICD-10, 1994. International Statistical Classification of Diseases and Related Health Problems. 10th Revision.
35. Johansen J.P., Cain C.K., Ostroff L.E., LeDoux J.E. Molecular mechanisms of fear learning and memory. Cell 2011, 147:509-524.
36. Julliard W., Fechner J.H., Mezrich J.D. The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front. Immunol. 2014, 5:1-6.
37. Kelley K.W., Bluthe R.-M., Dantzer R., Zhou J.-H., Shen W.-H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17:S112-S118.
38. Kendler K.S., Hettema J.M., Butera F., Gardner C.O., Prescott C.A. Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch. Gen. Psychiatry 2003, 60:789-796.
39. Kessler R.C. The effects of stressful life events on depression. Annu. Rev. Psychol. 1997, 48:191-214.
40. Kiank C., Zeden J.-P., Drude S., Domanska G., Fusch G., Otten W., Schuett C. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 2010, 5:e11825.
41. Kim J.J., Jung M.W. Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci. Biobehav. Rev. 2006, 30:188-202.
42. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954.
43. Kimura K., Moriwaka H., Nagaki M., Saio M., Nakamoto Y., Naito M., Kuwata K., Chisari F.V. Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. Am. J. Pathol. 2006, 168:786-795.
44. Laugeray A., Launay J.-M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav. Brain Res. 2010, 210:84-91.
45. Lawson M.A., Parrott J.M., McCusker R.H., Dantzer R., Kelley K.W., O'Connor J.C. Intracerebroventricular administration of lipopolysaccharide induces indloeamine-2,3-doxygenase-dependent depression-like behaviors. J. Neuroinflammation 2013, 10:87.
46. LeDoux J. Rethinking the emotional brain. Neuron 2012, 73:653-676.
47. Leo R., Di Lorenzo G., Tesauro M., Razzini C., Forleo G.B., Chiricolo G., Cola C., Zanasi M., Troisi A., Siracusano A., Lauro R., Romeo F. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J. Clin. Psychiatry 2006, 67:1760-1766.
48. Li Q., Korzan W.J., Ferrero D.M., Chang R.B., Roy D.S., Buchi M., Lemon J.K., Kaur A.W., Stowers L., Fendt M., Liberles S.D. Synchronous evolution of an odor biosynthesis pathway and behavioral response. Curr. Biol. 2013, 23:11-20.
49. Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M., Waeltz P., Bowman K.J., Polam P., Sparks R.B., Yue E.W., Li Y., Wynn R., Fridman J.S., Burn T.C., Combs A.P., Newton R.C., Scherle P.A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
50. Lob S., Konigsrainer A., Schafer R., Rammensee H.-G., Opelz G., Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2014, 111:2152-2154.
51. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
52. Maren S., Phan K.L., Liberzon I. The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 2013, 14:417-428.
53. Marques-Vidal P., Bochud M., Bastardot F., Lüscher T., Ferrero F., Gaspoz J.-M., Paccaud F., Urwyler A., von Känel R., Hock C., Waber G., Preisig M., Vollenweider P. Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus Study). PLoS One 2011, 6:e21002.
54. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4:762-774.
55. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
56. Miura H., Ando Y., Noda Y., Isobe K., Ozaki N. Long-lasting effects of inescapable-predator stress on brain tryptophan metabolism and the behavior of juvenile mice. Stress 2011, 14:262-272.
57. Müller A., Strauss L., Greter M., Gast H., Recher M., Becher B., Fontana A. Neutralization of colony-stimulating factor 1 receptor prevents sickness behavior syndrome by reprogramming inflammatory monocytes to produce IL-10. Brain. Behav. Immun. 2015, 48:78-85.
58. Munroe M.E. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin. Immunol. 2009, 21:283-288.
59. Neubauer H., Petrak F., Zahn D., Pepinghege F., Hägele A.-K., Pirkl P.-A., Uhl I., Juckel G., Mügge A., Herpertz S. Newly diagnosed depression is associated with increased beta-thromboglobulin levels and increased expression of platelet activation markers and platelet derived CD40-CD40L. J. Psychiatr. Res. 2013, 47:865-871.
60. Nikolaus S., Bode C., Taal E., van de Laar M.A.F.J. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res. 2013, 65:1128-1146.
61. Nissen C., Holz J., Blechert J., Feige B., Riemann D., Voderholzer U., Normann C. Learning as a model for neural plasticity in major depression. Biol. Psychiatry 2010, 68:544-552.
62. O'Connor J.C., André C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon-y and tumor necrosis factor-a mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to Bacillus Calmette-Guérin. J. Neurosci. 2009, 29:4200-4209.
63. O'Connor J.C., Lawson M.A., André C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indolemaine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
64. Pacheco-Lopez G., Bermudez-Rattoni F. Brain-immune interactions and the neural basis of disease-avoidant ingestive behavior. Philos. Trans. R Soc. B 2011, 366:3389-3405.
65. Peters A.L., Stunz L.L., Bishop G.A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 2009, 21:293-300.
66. Pryce C.R., Azzinnari D., Sigrist H., Gschwind T., Lesch K.-P., Seifritz E. Establishing a learned helplessness effect paradigm in C57BL/6 mice. behavioural evidence for emotional, motivational and cognitive effects of aversive uncontrollability per se. Neuropharmacology 2012, 62:358-372.
67. Pugh C.R., Kumagawa K., Fleshner M., Watkins L.R., Maier S.F., Rudy J.W. Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behav. Immun. 1998, 12:212-229.
68. Raison C.L., Miller A.H. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav. Immun. 2013, 31:1-8.
69. Rescorla R.A. Pavlovian conditioning: it's not what you think it is. Am. Psychol. 1988, 43:151-160.
70. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom. Med. 2014, 76:181-189.
71. Salazar A., Gonsalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 2012, 62:202-209.
72. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
73. Selzhammer V., Guest P.C., Rothermundt M., Sondermann C., Michael N., Schwarz E., Rahmoune H., Bahn S. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur. Neuropsychopharmacol. 2013, 23:1199-1207.
74. Siegert R.J., Abernethy D.A. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2004, 76:469-475.
75. Taguchi A., Niwa M., Hoshi M., Saito K., Masutani T., Hisamatsu K., Kobayashi K., Hatano Y., Tomita H., Hara A. Indoleamine 2,3-dioxygenase 1 is upregulated in activated microglia in mice cerebellum during acute viral encephalitis. Neurosci. Lett. 2014, 564:120-125.
76. Taraborrelli C., Palchykova S., Tobler I., Gast H., Birchler T., Fontana A. TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation. Brain Behav. Immun. 2011, 25:434-442.
77. Thomson L.M., Sutherland R.J. Systemic administration of lipopolysaccharide and interleukin-1B have different effects on memory consolidation. Brain Res. Bull. 2005, 67:24-29.
78. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.-C., Finkelstein J., Kim S.-Y., Adhikari A., Thompson K.R., Andalman A.S., Gunaydin L.A., Witten I.B., Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-543.
79. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Broon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
80. Vignali D.A.A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 2000, 243:243-255.
81. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134:319-329.
82. Yu T., Guo M., Garza J., Rendon S., Sun X.L., Zhang W., Lu X.Y. Cognitive and neural correlates of depression-like behaviour in socially defeated mice. An animal model of depression with cognitive dysfunction. Int. J. Neuropsychopharmacol. 2011, 14:303-317.
83. Yue E.W., Douty B., Wayland B., Bower M., Liu X., Leffet L., Wang Q., Bowman K.J., Hansbury M.J., Liu C., Wei M., Li Y., Wynn R., Burn T.C., Koblish H.K., Fridman J.S., Metcalf B., Scherle P.A., Combs A.P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 2009, 52:7364-7367.
84. Zhou F., Ajuebor M.N., Beck P.L., Le T., Hogaboam C.M., Swain M.G. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology 2005, 42:372-380.